Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Cabozantinib vs Sunitinib in Untreated Advanced or Metastatic Renal Cell Carcinoma
2023-509711-83-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of nivolumab, cabozantinib, sunitinib and ipilimumab in renal cell carcinoma (RCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival per BICR of Arm A versus Arm C. Started Apr 2024; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-509711-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509711-83-00.